Literature DB >> 7915082

cAMP can raise or lower cardiac actomyosin ATPase activity depending on alpha-adrenergic activity.

G McClellan1, A Weisberg, S Winegrad.   

Abstract

Adenosine 3',5'-cyclic monophosphate (cAMP) or beta-adrenergic stimulation has been shown to increase actomyosin adenosinetriphosphatase (ATPase) activity in cardiac muscle. Because the major catecholamine transmitters have both alpha- and beta-adrenergic activity, the possibility of a role for alpha-adrenergic stimulation in the regulation of ATPase activity has been investigated. Histochemical measurement of actomyosin ATPase activity in quickly frozen rat hearts has been used as the assay of enzymatic function of the contractile proteins. The dose-response curve of ATPase activity to cAMP shows an increase in ATPase activity at a threshold concentration of 0.01 microM, a peak effect at 0.5-1.0 microM, and a decline beyond 1.5 microM to a level below control at 10 microM cAMP. Kinetic studies varying ATP concentration from 0.5 to 10 mM indicated the existence of multiple forms of actomyosin ATPase activity in the absence of cAMP and only one form with a higher maximum velocity in the presence of 1 microM cAMP. Apparently cAMP raises the enzymatic activity of the individual actomyosin molecule rather than increasing the number of active molecules. The addition of an alpha-adrenergic blocker had no significant effect in the absence of added cAMP, but in the presence of the cyclic nucleotide, 1 microM prazosin always produced a negative effect on ATPase activity. Over the entire range of 0.01-10 microM, cAMP lowered ATPase activity when the alpha-adrenergic antagonist was present. The integrity of the cAMP regulatory system was sensitive to the tissue oxygen tension at the time the heart was quickly frozen. At certain oxygen tension, the stimulatory component of the cAMP regulation was observed without any inhibitory component, suggesting that there are two relatively independent parts of the regulatory mechanism, an inhibitory and a stimulatory. In the presence of gamma-labeled [32P]ATP, 32P was incorporated into several proteins, including the inhibitory subunit of troponin (TNI), C protein, and the regulatory light chain of myosin. cAMP (1 microM) caused an increase in 32P labeling of TNI and C protein. The addition of prazosin with cAMP caused a decrease in the overall level of phosphorylation with specific dephosphorylation of C protein and TNI, the former to a degree similar to the decrease in actomyosin ATPase activity, the latter to a greater degree. These results indicate that alpha-adrenergic activity modulates the balance between kinase and phosphatase activity in the presence of cAMP, probably by inhibiting phosphatase activity.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7915082     DOI: 10.1152/ajpheart.1994.267.2.H431

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  10 in total

1.  Phosphorylation of cMyBP-C affects contractile mechanisms in a site-specific manner.

Authors:  Li Wang; Xiang Ji; David Barefield; Sakthivel Sadayappan; Masakata Kawai
Journal:  Biophys J       Date:  2014-03-04       Impact factor: 4.033

2.  Changes in cardiac contractility related to calcium-mediated changes in phosphorylation of myosin-binding protein C.

Authors:  G McClellan; I Kulikovskaya; S Winegrad
Journal:  Biophys J       Date:  2001-08       Impact factor: 4.033

3.  Multiple structures of thick filaments in resting cardiac muscle and their influence on cross-bridge interactions.

Authors:  R Levine; A Weisberg; I Kulikovskaya; G McClellan; S Winegrad
Journal:  Biophys J       Date:  2001-08       Impact factor: 4.033

4.  A critical function for Ser-282 in cardiac Myosin binding protein-C phosphorylation and cardiac function.

Authors:  Sakthivel Sadayappan; James Gulick; Hanna Osinska; David Barefield; Friederike Cuello; Metin Avkiran; Valerie M Lasko; John N Lorenz; Marjorie Maillet; Jody L Martin; Joan Heller Brown; Donald M Bers; Jeffery D Molkentin; Jeanne James; Jeffrey Robbins
Journal:  Circ Res       Date:  2011-05-19       Impact factor: 17.367

Review 5.  Lipids: a Potential Molecular Pathway Towards Diastolic Dysfunction in Youth-Onset Type 2 Diabetes.

Authors:  Amy S Shah; Sakthivel Sadayappan; Elaine M Urbina
Journal:  Curr Atheroscler Rep       Date:  2022-01-24       Impact factor: 5.113

6.  Cardiac myosin binding protein-C phosphorylation in a {beta}-myosin heavy chain background.

Authors:  Sakthivel Sadayappan; James Gulick; Raisa Klevitsky; John N Lorenz; Michelle Sargent; Jeffery D Molkentin; Jeffrey Robbins
Journal:  Circulation       Date:  2009-02-23       Impact factor: 29.690

Review 7.  Phosphorylation and function of cardiac myosin binding protein-C in health and disease.

Authors:  David Barefield; Sakthivel Sadayappan
Journal:  J Mol Cell Cardiol       Date:  2009-12-03       Impact factor: 5.000

8.  Alteration of myosin cross bridges by phosphorylation of myosin-binding protein C in cardiac muscle.

Authors:  A Weisberg; S Winegrad
Journal:  Proc Natl Acad Sci U S A       Date:  1996-08-20       Impact factor: 11.205

9.  Effect of MyBP-C binding to actin on contractility in heart muscle.

Authors:  Irina Kulikovskaya; George McClellan; Jeanne Flavigny; Lucie Carrier; Saul Winegrad
Journal:  J Gen Physiol       Date:  2003-12       Impact factor: 4.086

10.  Multiple forms of cardiac myosin-binding protein C exist and can regulate thick filament stability.

Authors:  Irina Kulikovskaya; George B McClellan; Rhea Levine; Saul Winegrad
Journal:  J Gen Physiol       Date:  2007-05       Impact factor: 4.086

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.